Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Return on Capital Employed (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed Return on Capital Employed for 5 consecutive years, with 0.6% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 18.0% to 0.6% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.6% through Dec 2025, down 18.0% year-over-year, with the annual reading at 0.48% for FY2025, 1.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.6% at TScan Therapeutics, down from 0.59% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.28% in Q4 2021, with the low at 0.6% in Q4 2025.
  • Average Return on Capital Employed over 5 years is 0.42%, with a median of 0.42% recorded in 2024.
  • The sharpest move saw Return on Capital Employed rose 10bps in 2023, then dropped -23bps in 2025.
  • Over 5 years, Return on Capital Employed stood at 0.28% in 2021, then tumbled by -45bps to 0.4% in 2022, then increased by 8bps to 0.37% in 2023, then dropped by -12bps to 0.42% in 2024, then crashed by -44bps to 0.6% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.6%, 0.59%, and 0.51% for Q4 2025, Q3 2025, and Q2 2025 respectively.